Before starting any GLP-1 program in 2026, patients are encouraged to ask their prescribing clinician and the dispensing pharmacy specific questions about dosing, proper storage, potential adverse reactions, drug interactions, current product availability, and whether an FDA-approved medication may be more appropriate for their individual situation
Whether its navigating the side effects of Wegovy, providing instructions on how to use the pens, how much you could expect to lose, or tips on improving the medications efficacy, we have you covered
The SURPASS clinical trial program, which evaluated tirzepatide in over 6,000 patients with type 2 diabetes, did not identify frequent urination as a statistically significant adverse event
To view a copy of this license, visit About this article Cite this article Garvey, W.T., Batterham, R.L., Bhatta, M